Hypercalcemia News and Research

RSS
Hypercalcemia or increased blood level of calcium is calcium found in a concentration that is higher than the usual range of 8.5 to 10.2 mg/dL. However, this normal value may vary slightly between different laboratories due to differences in protocols.

Further Reading

Unigene acquires exclusive worldwide rights to oral PTH program from GSK

Unigene acquires exclusive worldwide rights to oral PTH program from GSK

Multi-center cabozantinib trial for hormone receptor-positive breast cancer with bone metastases initiated

Multi-center cabozantinib trial for hormone receptor-positive breast cancer with bone metastases initiated

First genetic, biochemical tests for Idiopathic Infantile Hypercalcemia

First genetic, biochemical tests for Idiopathic Infantile Hypercalcemia

Calcium-sensing receptor plays key role in lethal lung cancer complication

Calcium-sensing receptor plays key role in lethal lung cancer complication

CytRx to present bafetinib preclinical study results at AACR Annual Meeting

CytRx to present bafetinib preclinical study results at AACR Annual Meeting

CytRx's bafetinib helps reduce skeletal complications in cancer patients

CytRx's bafetinib helps reduce skeletal complications in cancer patients

TransPharma reports positive results from ViaDerm-Calcitonin Phase 1 trial for musculoskeletal disorders

TransPharma reports positive results from ViaDerm-Calcitonin Phase 1 trial for musculoskeletal disorders

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

Keryx announces positive top-line results from Zerenex Phase 3 study for hyperphosphatemia

Keryx announces positive top-line results from Zerenex Phase 3 study for hyperphosphatemia

FDA warns of risk of atypical thigh bone fracture in patients taking bisphosphonates

FDA warns of risk of atypical thigh bone fracture in patients taking bisphosphonates

Positive results from new analyses of denosumab Phase 3 trials

Positive results from new analyses of denosumab Phase 3 trials

Initial results of gallium-containing compound to treat serious infection presented at AACR 2010

Initial results of gallium-containing compound to treat serious infection presented at AACR 2010

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

Study results of PTH1-34 oral parathyroid hormone presented

Study results of PTH1-34 oral parathyroid hormone presented

Amgen announces results of Phase 3 head-to-head trial evaluating denosumab versus Zometa

Amgen announces results of Phase 3 head-to-head trial evaluating denosumab versus Zometa

Book on pediatric bone disorders and mineral metabolism

Book on pediatric bone disorders and mineral metabolism

Amgen announces results of Phase 3 trial in the treatment of bone metastases

Amgen announces results of Phase 3 trial in the treatment of bone metastases

Zosano Pharma presents positive results for needle-free osteoporosis therapy

Zosano Pharma presents positive results for needle-free osteoporosis therapy

Genta Incorporated issued two key U.S. patents for gallium products franchise

Genta Incorporated issued two key U.S. patents for gallium products franchise

Sun Pharmaceutical receives FDA approvals for 4 generics

Sun Pharmaceutical receives FDA approvals for 4 generics

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.